Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 2, 2007

View Archived Issues

Hana Biosciences presents new data on compounds utilizing its Optisome technology

Medivir presents third quarter 2007 results

Recent patents describe novel agents for anxiety, psychosis and sleep disorders

New antiglaucoma agents reported in recent Allergan patent

Recent Ranbaxy patent discloses new therapeutic agents for urinary incontinence

CAM-24 shows antipsychotic activity in vivo with low potential for motor side effects

SNAP25 may be a common susceptibility gene for ADHD and early-onset bipolar affective disorder

European Commission grants marketing authorization for Nexavar

The Hsp90 inhibitor NVP-AUY-922 profiled at the AACR-NCI-EORTC meeting

Epix reports positive results from phase IIb clinical trial of PRX-07034 in obesity

Peptech successfully completes phase I trial for PN-0621

Results of BEYOND study in Betaferon do not support regulatory filing for 500 mcg dose

Pharming completes randomized treatments in clinical trial of Rhucin

TST-10088 well tolerated in ongoing phase I study

Favorable results seen in phase I study of XMT-1001

Threshold updates corporate activities and clinical development

Relypsa formed as a spin-out company of Amgen and Ilypsa

Battelle acquires the assets of Ventaira Pharmaceuticals

Eli Lilly and Glenmark enter license agreement for GRC-6211

Adherex initiates collaborative phase III trial of sodium thiosulfate

Forbes Medi-Tech close to compound selection in FM-TP2000 and FM-TP3000 series

Sciele and Plethora initiate patient enrollment in phase III trials of PSD-502

Nycomed to acquire Bradley Pharmaceuticals

Inovio and Tripep begin enrollment of patients for phase I/II clinical trial of ChronVac-C

Bayer HealthCare submits rivaroxaban MAA to the EMEA

Meda submits NDA for BEMA Fentanyl to FDA

FDA approves Allergan's Combigan for reduction of intraocular pressure

Results from phase III registration trial of satraplatin fail to achieve statistical significance

U.K. grants marketing authorization to Javelin's Dyloject for acute pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...